The Impact of High-frequency Transcranial Alternating Current Stimulation (Hi-tACS) on Cognitive Function in Patients With Schizophrenia

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This study is a double-blind, randomized, controlled intervention study aimed at exploring whether high-frequency transcranial alternating current stimulation (Hi-tACS) can improve cognitive impairment in patients with schizophrenia.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Meets the diagnostic criteria for schizophrenia according to DSM-5.

• Age ≥ 18 years old.

• Right-handed.

• Willing to participate in this study and sign an informed consent form. If the participant is unable to read and sign the informed consent form due to lack of capacity, a legal guardian must act as a proxy during the informed consent process and sign the form.

• Clinically stable, receiving antipsychotic medication treatment with a stable dose for 4 weeks without any changes.

• Montreal Cognitive Assessment score ≥ 10 points.

Locations
Other Locations
China
Sir Run Run Shaw Hospital
RECRUITING
Hanzhou
Quzhou Third Hospital
RECRUITING
Quzhou
Contact Information
Primary
Jinsong Tang, Doctorate
tangjinsong@zju.edu.cn
+8613627311963
Time Frame
Start Date: 2024-04-01
Estimated Completion Date: 2026-04-01
Participants
Target number of participants: 100
Treatments
Active_comparator: treatment arm
The frequency of the stimulation was 77.5Hz and the intensity was 15mA. Each participant was treated twice a day for 40 minutes each time, with an interval of more than 3 hours between the two sessions for 30 days
Sham_comparator: sham-treatment arm
The frequency of the stimulation was 77.5Hz and the intensity was 0mA. Each participant was treated twice a day for 40 minutes each time, with an interval of more than 3 hours between the two sessions for 30 days
Related Therapeutic Areas
Schizophrenia
Sponsors
Collaborators: Quzhou Third hospital
Leads: Sir Run Run Shaw Hospital

This content was sourced from clinicaltrials.gov

Similar Clinical Trials

A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Food Effects of a Single Oral VV119 Capsule in Healthy Chinese Volunteers

A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Food Effects of a Single Oral VV119 Capsule in Healthy Chinese Volunteers

Enrollment Status: Recruiting
Publish Date: June 11, 2025
Intervention Type: Drug
Study Phase: Phase 1

An Adaptive Phase II/III, Double-Blind, Randomized, Placebo-controlled, Two-Part, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®,a D-Amino Acid Oxidase Inhibitor, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults

An Adaptive Phase II/III, Double-Blind, Randomized, Placebo-controlled, Two-Part, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®,a D-Amino Acid Oxidase Inhibitor, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults

Who is this study for: Adult patients with schizophrenia
Enrollment Status: Recruiting
Publish Date: September 13, 2021
Intervention Type: Drug, Other
Study Drug: NaBen®
Study Phase: Phase 2/Phase 3

Antipsychotic Response to Clozapine in B-SNIP Biotype-1 (Clozapine)

Antipsychotic Response to Clozapine in B-SNIP Biotype-1 (Clozapine)

Who is this study for: Patients with Schizoaffective Disorder
Enrollment Status: Recruiting
Publish Date: August 28, 2025
Intervention Type: Drug
Study Drugs: Clozapine, Risperidone
Study Phase: Phase 4
View All